Pharmaceutical Business review

Neurotez receives US patent for hormone Leptin

Patent issuance comes as Neurotez completes GMP manufacturing of recombinant Leptin and prepares for IND-enabling studies.

Preclinical in vitro data and in vivo and interventional studies, along with human epidemiological studies, suggest that Leptin can be a promising therapy for the treatment of Alzheimer’s disease.

Neurotez president and CEO Nikolaos Tezapsidis said, "The uniqueness of our therapy is that we are dealing with the replacement of an endogenous pluripotent hormone, that we have shown it improves cognition, and ameliorates pathobiology."

Leptin may have a physiologic role as a liporegulatory hormone for neural cells, and several molecular targets have been identified related to metabolic pathways that mediate Leptin’s action.